Sovaldi uptake strong despite pricing controversy

|By:, SA News Editor

33,672 prescriptions for Gilead's (GILD) Hep C treatment Sovaldi were filled in the first 12 weeks of commercial availability. Sales could reach $5B the first year making it the most successful pharmaceutical product launch ever.

Profit margins of insurers such as Molina Healthcare (MOH) and Express Scripts (ESRX) will be under pressure as the demand for the highly-effective drug skyrockets in tandem with no competition.

Gilead faces criticism from certain observers over its $84,000 full regimen price.